ROME (Reuters) -Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO 0.63%) were lower by 4% as of 11 a.m. ET today. The move comes as ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

Investing.com -- Italian authorities appointed a special commissioner on Monday to help Novo Nordisk (NYSE: NVO) deliver its planned €2 billion ($2.34 billion) investment in a factory near Rome.

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

As part of Novo Holdings' takeover of pharmaceutical company Catalent last year, Novo Nordisk acquired a site in Italy along ...